BioSpace News Archive

Neuronetics, Inc. today announced that it plans to release second quarter 2023 financial and operating results prior to market open on Tuesday, August 8th, 2023.

Avenue Therapeutics, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (“FDA”) on key elements of the Phase 3 safety study, including the primary endpoint and statistical analysis approach, for intravenous (IV) tramadol.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, has installed the first SRT-100™ System in Ireland at Dublin’s Beacon Hospital.

BioSig Technologies, Inc. today announced the completion of a seed funding round raising $2.2 million for BioSig AI Sciences, Inc. (“BAIS”), a subsidiary of the Company.

Third Harmonic Bio, Inc. today announced its next-generation product candidate, THB335, a potent, highly selective oral small molecule KIT inhibitor with a meaningfully differentiated product profile as compared to the company’s first-generation product candidate THB001.

Evoke Pharma, Inc. today announced that its abstract entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” will be presented, as an oral plenary presentation, at the American College of Gastroenterology annual meeting taking place in Vancouver, BC, Canada from October 20-25, 2023.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its second quarter 2023 financial and operating results on Tuesday, August 8, 2023, following the close of trading.

Combined Therapeutics, Inc. today announced the participation of Dr. Romain Micol, President and CEO of Combined Therapeutics, as a featured speaker at the 3rd mRNA-Based Therapeutics Summit.

Blue Earth Diagnostics today announced that its optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent, POSLUMA® (flotufolastat F 18) injection.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that LIVMARLI® (maralixibat oral solution) has been authorized by Health Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).